Poster

Antitumor activity of BLU-945 and BLU-701 as single agents and in combination in EGFR L858R-driven models of NSCLC

Author

Luz Tavera

Condition

EGFR-mutated NSCLC

Drug target

EGFR mutants with L858R, T790M, C797S mutations

Drug moa

reversible and selective inhibition of EGFR mutations

Source url

s3://convoke-optic-posters/2024-05-10/Blueprint-Medicines-AACR-2022-BLU-945-BLU-701-EGFR-Mutant-NSCLC-Single-Agent-Combination-Preclinical-Poster.pdf

1 organization

1 product

Product

Organization